Do I need HRT? How hormone testing can help you decide

Symptoms are the primary diagnostic tool

NICE guidelines are clear on this point: for women over 45 who are experiencing typical perimenopause or menopause symptoms, a diagnosis can be made on the basis of age and symptoms without a blood test. Classic symptoms include hot flushes, night sweats, sleep disruption, low mood, brain fog, reduced libido, joint pain, vaginal dryness, and changes in the menstrual cycle. If these symptoms are present and your age fits the expected window, most GP or menopause specialist consultations will begin with a thorough symptom review rather than blood tests.

When perimenopause is harder to diagnose

The perimenopause, which can last several years before the final menstrual period, is the most diagnostically challenging phase. Hormone levels during this time fluctuate significantly from day to day and even hour to hour. This is precisely why a single oestrogen or FSH blood test can be misleading: a result within the "normal" range does not rule out perimenopause, and many women experience significant symptoms while their blood tests look unremarkable. As one British Menopause Society council member has noted, it is possible to have entirely normal blood results alongside very significant menopausal symptoms.

Age under 45 and premature ovarian insufficiency

For women under 45 experiencing menopause symptoms, blood testing becomes essential rather than optional. Premature ovarian insufficiency (POI) is diagnosed when the ovaries stop functioning normally before age 40, and it affects around 1 in 100 women. Two blood tests measuring FSH (follicle-stimulating hormone) taken 4-6 weeks apart are required to confirm POI, because a single elevated result is insufficient. POI carries different health implications from typical menopause, including a higher risk of bone density loss and cardiovascular changes, making early diagnosis and appropriate HRT particularly important.

Conditions that can mimic menopause symptoms

Before attributing all symptoms to menopause, it is worth ruling out other conditions that produce an overlapping picture. Hypothyroidism causes fatigue, low mood, brain fog, weight gain, and hair thinning: the same pattern that many women in their 40s attribute to the start of the menopausal transition. Anaemia from low ferritin produces exhaustion and cognitive sluggishness. Vitamin D deficiency contributes to low mood and joint pain. These conditions are treatable in their own right and do not improve with HRT. A blood panel that assesses these co-factors gives a fuller picture of what is driving the symptom burden before a treatment decision is made.

Testing before starting testosterone therapy

Testosterone is prescribed for some women alongside standard HRT to support libido, mood, energy, and cognitive function. British Menopause Society guidelines require baseline measurement of total testosterone and SHBG (sex hormone-binding globulin) before starting testosterone, and periodic monitoring thereafter, to ensure levels remain within a physiologically appropriate female range. This is one of the specific scenarios where a blood test directly informs HRT management.

Monitoring HRT when symptoms are not resolving

If you are already on HRT and your symptoms are continuing or worsening despite dose adjustments, blood testing can clarify whether the issue is one of absorption. Some women do not absorb transdermal oestrogen effectively through the skin, particularly with lower doses. Checking oestradiol levels 4-6 hours after applying a transdermal product can reveal whether an adequate amount is reaching the bloodstream. Similarly, if symptoms persist at a dose that appears adequate on paper, an oestradiol measurement helps distinguish between poor absorption, rapid metabolism, and the possibility that something else is contributing to symptoms.

The most useful starting point is a comprehensive blood panel that rules out the conditions most likely to complicate or mimic the menopause picture, rather than focusing solely on hormone levels that will fluctuate regardless.

TSH, Free T4, and Free T3 assess thyroid function. Hypothyroidism is significantly more common in women, particularly in their 40s and 50s, and produces symptoms that overlap almost precisely with perimenopause. A thyroid panel alongside hormonal assessment prevents misattribution of thyroid symptoms to menopause.

Ferritin reflects iron storage. Low ferritin causes fatigue, brain fog, and hair thinning that can be severe enough to dominate a woman's symptom experience during perimenopause. It is also common in women who have had heavy periods during the perimenopausal transition.

Vitamin D deficiency is associated with low mood, joint pain, and fatigue. It also affects bone health, which becomes particularly relevant during the menopausal transition when oestrogen-driven bone protection reduces.

Vitamin B12 is relevant because B12 deficiency produces cognitive symptoms and low mood that are easy to conflate with hormonal changes, and because B12 is directly involved in methylation pathways that affect how the body processes hormones.

Lipid panel (LDL, HDL, total cholesterol, triglycerides) is increasingly important at the menopausal transition. Oestrogen has a protective effect on cardiovascular lipid profiles; as levels decline, LDL tends to rise and HDL may fall. Establishing a baseline lipid profile at perimenopause and tracking changes over time is part of a comprehensive approach to long-term cardiovascular health.

HbA1c gives a three-month average of blood sugar control, relevant because insulin resistance becomes more common around menopause and contributes to weight gain, fatigue, and cardiovascular risk.

CRP (C-reactive protein) measures systemic inflammation, which increases with the menopausal transition and can amplify other symptoms.

Homocysteine reflects methylation pathway efficiency. Elevated homocysteine is associated with cardiovascular risk and is influenced by B12, folate, and MTHFR gene variants: all factors that can intersect with the hormonal changes of menopause in ways that affect long-term health outcomes.

For specific hormone testing (oestradiol, FSH, LH, testosterone, SHBG), your GP can request these through the NHS if clinically indicated, or they can be accessed through private menopause clinics and some home testing providers. If you are over 45 and experiencing typical symptoms, NHS guidance does not require these tests before starting HRT.

Strength training and bone protection

As oestrogen levels decline, bone density can reduce. Resistance exercise stimulates bone remodelling and helps preserve both muscle mass and skeletal strength during the menopausal transition. Evidence supports weight-bearing and resistance activity specifically for bone health outcomes, alongside its effect on mood, metabolic health, and sleep quality.

Nutrition, methylation, and cardiovascular risk

The menopausal transition shifts the cardiovascular risk profile in a way that dietary choices can meaningfully influence. A diet lower in refined carbohydrates and saturated fat, higher in omega-3 fatty acids and fibre, and rich in B vitamins (B6, B12, folate) supports both lipid management and homocysteine clearance. Tracking lipid and homocysteine levels over time is one of the most direct ways to see whether your dietary and lifestyle choices are moving your cardiovascular markers in the right direction.

Sleep quality and circadian rhythm support

Poor sleep is one of the most commonly reported and impactful symptoms of the menopause transition, driven by a combination of night sweats, changing sleep architecture, and altered cortisol patterns. Sleep disruption amplifies mood, cognitive, and energy symptoms significantly. Consistent sleep timing, a cooler sleeping environment, and reducing alcohol (which disrupts sleep architecture and can worsen night sweats) are among the most evidence-based practical changes available.

Managing inflammation as a long-term priority

Low-grade systemic inflammation tends to increase around menopause. A Mediterranean-style dietary pattern, regular moderate exercise, and management of chronic stressors all reduce inflammatory load as measured by CRP and other inflammatory markers. Tracking CRP as part of your ongoing biomarker monitoring gives you a way to see whether your choices are having a measurable effect on inflammatory status over time.